Likely Leqembi nod could unlock billions for Biogen and Eisai

8 June 2023
brain_alzheimer-s_neurology_neuroscience_big

Ahead of a key meeting from the US Food and Drug Administration’s scientific advisory panel,  briefing notes reveal a broadly positive view of Eisai (TYO: 4523) and Biogen’s (Nasdaq: BIIB) new Alzheimer’s med.

The companies received an Accelerated Approval for Leqembi (lecanemab), an antibody which clears errant plaques of protein in the brain, at the start of the year.

That decision was based on mid-stage data from the ATHENA AD trial, which showed the biologic cleared the plaques and generated a statistically significant reduction in cognitive decline for some patients with early signs of disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology